T1	Pharmacological_substance 20 32	erythromycin
N1000 	Reference T1 MeSH:D004917	erythromycin
T2	Pharmacological_substance 34 45	fluvoxamine
N1001 	Reference T2 MeSH:D016666	fluvoxamine
T3	Pharmacological_substance 96 107	ropivacaine
N1002 	Reference T3 MeSH:C037663	ropivacaine
T4	Pharmacological_substance 137 148	fluvoxamine
N1003 	Reference T4 MeSH:D016666	fluvoxamine
T5	Pharmacological_substance 153 165	erythromycin
N1004 	Reference T5 MeSH:D004917	erythromycin
T6	Pharmacological_substance 193 204	ropivacaine
N1005 	Reference T6 MeSH:C037663	ropivacaine
T8	Pharmacological_substance 314 326	erythromycin
N1006 	Reference T8 MeSH:D004917	erythromycin
T10	Pharmacological_substance 346 357	fluvoxamine
N1007 	Reference T10 MeSH:D016666	fluvoxamine
T11	Pharmacological_substance 386 398	erythromycin
N1008 	Reference T11 MeSH:D004917	erythromycin
T12	Pharmacological_substance 403 414	fluvoxamine
N1009 	Reference T12 MeSH:D016666	fluvoxamine
T14	Pharmacological_substance 488 499	ropivacaine
N1010 	Reference T14 MeSH:C037663	ropivacaine
T15	Pharmacological_substance 517 528	Ropivacaine
N1011 	Reference T15 MeSH:C037663	Ropivacaine
T16	Pharmacological_substance 530 550	3-hydroxyropivacaine
T17	Pharmacological_substance 556 578	2',6'-pipecoloxylidide
N1012 	Reference T17 MeSH:C025149	2',6'-pipecoloxylidide
T18	Pharmacological_substance 673 684	Fluvoxamine
N1013 	Reference T18 MeSH:D016666	Fluvoxamine
T19	Pharmacological_substance 760 771	ropivacaine
N1014 	Reference T19 MeSH:C037663	ropivacaine
T24	Pharmacological_substance 927 939	Erythromycin
N1015 	Reference T24 MeSH:D004917	Erythromycin
T25	Pharmacological_substance 997 1008	ropivacaine
N1016 	Reference T25 MeSH:C037663	ropivacaine
T26	Pharmacological_substance 1045 1056	fluvoxamine
N1017 	Reference T26 MeSH:D016666	fluvoxamine
T27	Pharmacological_substance 1083 1094	fluvoxamine
N1018 	Reference T27 MeSH:D016666	fluvoxamine
T28	Pharmacological_substance 1099 1111	erythromycin
N1019 	Reference T28 MeSH:D004917	erythromycin
T30	Pharmacological_substance 1200 1211	ropivacaine
N1020 	Reference T30 MeSH:C037663	ropivacaine
T34	Pharmacological_substance 1280 1291	fluvoxamine
N1021 	Reference T34 MeSH:D016666	fluvoxamine
T35	Pharmacological_substance 1328 1339	ropivacaine
N1022 	Reference T35 MeSH:C037663	ropivacaine
T36	Pharmacological_substance 1367 1378	fluvoxamine
N1023 	Reference T36 MeSH:D016666	fluvoxamine
T39	Pharmacological_substance 1400 1412	erythromycin
N1024 	Reference T39 MeSH:D004917	erythromycin
T40	Pharmacological_substance 1438 1449	ropivacaine
N1025 	Reference T40 MeSH:C037663	ropivacaine
T41	Disorder 1568 1576	toxicity
N1 	Reference T41 UMLS:C0600688	toxicity
T42	Pharmacological_substance 1580 1591	ropivacaine
N1026 	Reference T42 MeSH:C037663	ropivacaine
T49	Pharmacological_substance 1705 1716	ropivacaine
N1027 	Reference T49 MeSH:C037663	ropivacaine
T51	Combination 1068 1079	combination
T53	Combination 1348 1359	Concomitant
T55	Pharmacological_substance 1616 1636	inhibitors of CYP1A2
N1028 	Reference T55 MeSH:D065609	inhibitors of CYP1A2
T57	Combination 1597 1610	used together
T60	Combination 1639 1650	Concomitant
T63	Pharmacological_substance 1658 1664;1677 1685	CYP1A2 nhibitor
T64	Combination 57 68	combination
T69	Subject 266 290	Eight healthy volunteers
T77	Pharmacological_substance 1669 1675;1676 1686	CYP3A4 inhibitors
N1029 	Reference T77 MeSH:D051544	CYP3A4 inhibitor
T78	Pharmacological_substance 419 426	placebo
N1030 	Reference T78 MeSH:D010919	placebo
T7	Speculation_cue 1543 1554	possibility
T13	Combination 399 402	and
